Results 201 to 210 of about 4,656 (255)
Some of the next articles are maybe not open access.

Simultaneous Quantitation of Paracetamol and Lornoxicam in Presence of Five Related Substances and Toxic Impurities by a Selective HPLC-DAD Method.

Journal of AOAC International, 2022
OBJECTIVE This research describes the simultaneous quantitation of Paracetamol (PRM) and Lornoxicam (LRX) with five of their related substances and toxic impurities, including, 4-nitrophenol (NTP), 4-aminophenol (AMP), 4-chloroacetanilide (CAC), N ...
Amira F. El-Yazbi   +3 more
semanticscholar   +1 more source

Development of immediate release tablet formulations of lornoxicam with hot melt extrusion-based three-dimensional printing technology

Drug Development and Industrial Pharmacy
Introduction This study aims to develop immediate release tablet formulations of lornoxicam (LRX) using hot melt extrusion (HME)-based fused deposition modeling (FDM) focusing on the adjustment of drug release by arranging infill densities and evaluating
Aysel Yılmaz   +2 more
semanticscholar   +1 more source

Lornoxicam Solid Lipid Nanoparticle-Enriched Transdermal Gel: Development and Characterization

International Journal of Drug Delivery Technology
To develop antiinflammation and analgesic effects, scientists introduced lornoxicam (LRX) nanoemulsion, nanostructure lipid carriers, and solid lipid nanoparticles.
Vaibhav Dagaji Aher   +3 more
semanticscholar   +1 more source

Formulation and Characterization of Emulgel Lornoxicam Containing Lemon Grass Oil as Penetration Enhancer.

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
INTRODUCTION Emulgel dosage form is an advanced form of transdermal drug de-livery. It is a combination of emulsion and gel in a definite ratio. Emulsions are incorporated into the gel with proper mixing. The emulsion present in emulgel can be either oil/
Vibha Kumari, Meenakshi Bajpai
semanticscholar   +1 more source

Fabrication and Characterization of Sustained-Release Eudragit RSPO Microsphere of Lornoxicam by Spray Drying Technique

Current Drug Therapy
Lornoxicam is a potent non-steroidal anti-inflammatory drug (NSAID) with strong analgesic properties; however, its short half-life necessitates frequent administration for sustained efficacy.
Hiren V. Patel   +3 more
semanticscholar   +1 more source

Lornoxicam

Drugs, 1996
Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a ...
J A, Balfour, A, Fitton, L B, Barradell
openaire   +2 more sources

Development and Validation of FTIR Spectroscopic Method for the Quantitative Estimation of Lornoxicam in Tablet Dosage Form.

International Journal of Pharmaceutical Quality Assurance
Lornoxicam is available in the market as a solid dosage form, particularly tablets. Liquid chromatography has been the recommended assay procedure for lornoxicam in various pharmacopeias.
M. Puranik   +3 more
semanticscholar   +1 more source

Transfersomal gel nanocarriers for enhancement the permeation of lornoxicam

, 2020
In respect to the major gastrointestinal disorders associated with oral administration of Lornoxicam, LOR, a potent anti-inflammatory drug, topical delivery could be an alternative route of administration.
Hesham M. Tawfeek   +4 more
semanticscholar   +1 more source

Lornoxicam in clinical practice.

Postgraduate medical journal, 1991
Three studies reported here have confirmed that lornoxicam is effective in osteoarthritis and the ideal dose appears to be 12 mg daily. Overall, lornoxicam appears to be a useful drug in the treatment of both osteo- and rheumatoid arthritis, from the data presently available.
H, Berry, S, Ollier
openaire   +1 more source

Pharmacokinetics of lornoxicam in man.

Postgraduate medical journal, 1991
Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam. Lornoxicam was administered as an aqueous solution both orally and intravenously to young, healthy, male volunteers. The total excretion of lornoxicam via urine and faeces after oral administration was determined by administering 14C-labelled ...
G, Hitzenberger   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy